Nausea and vomiting associated with selective serotonin reuptake inhibitors: Incidence, mechanisms and management

CNS Drugs

Volumn 8, Issue 5, 1997, Pages 394-401

  McManis, Philip G ^a,b   Talley, Nicholas J ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b NEPEAN HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CISAPRIDE; FLUOXETINE; FLUVOXAMINE; METOCLOPRAMIDE; MONOAMINE OXIDASE INHIBITOR; ONDANSETRON; PROCHLORPERAZINE; PROMETHAZINE; RECEPTOR SUBTYPE; SEROTONIN; SEROTONIN 3 ANTAGONIST; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ANOREXIA; ANXIETY NEUROSIS; BLOOD BRAIN BARRIER; CARCINOID SYNDROME; DEPRESSION; DIARRHEA; DRUG MECHANISM; GASTROINTESTINAL SYMPTOM; HUMAN; INSOMNIA; NAUSEA; NERVOUSNESS; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; REVIEW; SEROTONIN RELEASE; TREMOR; VOMITING; WITHDRAWAL SYNDROME; XEROSTOMIA;

EID: 0030727147     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199708050-00005     Document Type: Review

References (45)

1. Bhandari P, Bingham S, Andrews PL. The neuropharmacology of loperamide-induced emesis in Ihe ferret: the role of the area postrema, vagus, opiate and 5-HT3 receptors. Neuropharmacology 1992; 31: 735-42
2. Bhargava KP, Dixit KS, Palit G. Nature of histamine receptors in the emetic chemoreceptor trigger zone. Br J Pharmacol 1976; 57: 211-3
3. Cubeddu LX, Huffman IS, Fuenmayor NT, et al. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. N Engl J Med 1990; 322: 810-6
4. Miller AD, Leslie RA. The area postrema and vomiting. Front Neuroendocrinol 1994; 15: 301-20
5. Hawthorn J, Andrews PL, Ang VT, et al. Differential release of vasopressin and oxytocin in response to abdominal vagal afferent stimulation or apomorphine in the ferret. Brain Res 1988; 438: 193-8
6. Lee M, Feldman M. Nausea and vomiting. In: Sleisenger MH, Fordtran JS, editors. Gastrointestinal disease: pathophysiology/diagnosis/munagement. 5th ed. Philadelphia (PA): WB Saunders. 1993: 509-19
7. Andrews PLR, Hawthorn J. The neurophysiology of vomiting. Baillieres Clin Gastroenterol 1988; 2: 141-68
8. Monthly index of medical specialities. 20th ed. London: Haymarket Medical Publications Ltd, 1996
9. Brymer C, Winograd CH. Fluoxetine in elderly patients: is there cause for concern? J Am Geriatr Soc 1992; 40: 902-5
10. Wong DT, Reid LR, Threlkeld PG. Suppression of food intake in rats by fluoxctine: comparison of enantiomers and effects of serotonin antagonists. Pharmacol Biochem Behav 1988; 31: 475-9
11. Wagner W, Zahorny BA, Gray TE. Fluvoxamine: a review of its safety profile in world-wide studies. Int Clin Psychopharmacol 1994; 9: 223-7
12. Bergeron R, Blier P. Cisapride for the treatment of nausea produced by selective serotonin reuptake inhibitors. Am J Psychiatry 1994; 151: 1084-6
13. Levine LR, Enas GC, Thompson WL, et al. Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study. Int J Obes 1989; 13: 635-45
14. Russell JL. Relatively low doses of cisapride in the treatment of nausea in patients treated with venlafaxine for treatment-refractory depression. J Clin Psychopharmacol 1996; 16: 35-7
15. Fritze J, Lanczik M. Pharmacokinetic interactions between carbamazepine and fluvoxamine [abstract]. Pharmacopsychiatry 1993; 26: 153
16. WHO Drug Information 1994; 8: 156
17. Zelwer A. Fluoxetine-tricyclic combinations. Aust NZ J Psychiatry 1993; 27: 350-2
18. Sporer KA. The serotonin syndrome: implicated drugs, pathophysiology and management. Drug Saf 1995; 13: 94-104
19. Power BM, Hackett LP, Dusci LJ, et al. Antidepressant toxicity and the need for identification and concentration monitoring in overdose. Clin Pharmacokinet 1995; 29: 154-71
20. Bodner RA, Lynch T, Lewis L, et al. Serotonin syndrome. Neurology 1995; 45: 219-23
21. Shader RI. Question the experts. J Clin Psychopharmacol 1993; 13:79
22. Hoyer D, Martin GR. Classification and nomenclature of 5-HT receptors: a comment on current issues. Behav Brain Res 1996; 73: 263-8
23. Tonini M, Candura SM, Messori E, et al. Therapeutic potential of drugs with mixed 5-HT4 agonist/5-HT3 antagonist action in the control of emesis. Pharmacol Res 1995; 31: 257-60
24. Talley NJ. 5-hydroxytryptamine agonists and antagonists in the modulation of gastrointestinal motility and sensation: clinical implications. Aliment Pharmacol Ther 1992; 6: 273-89
25. Costall B, Naylor RJ. 5-hydroxytryptamine: new receptors and novel drugs for gastrointestinal motor disorders. Scand J Gastroenterol 1990; 25: 769-87
26. Bradley PB, Engel G, Feniuk W, et al. Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacology 1986; 25: 563-76
27. Ng WW, Jing J, Hyman PE, et al. Effect of 5-hydroxytryptamine and its antagonists on colonic smooth muscle of the rabbit. Dig Dis Sci 1991; 36: 168-73
28. Baez M, Yu L, Cohen ML. Pharmacological and molecular evidence that the contractile response to serotonin in rat stomach fundus is not mediated by activation of the 5-hydroxytryptamine 1C receptor. Mol Pharmacol 1990; 38: 31-7
29. Gore S, Gilmore IT, Haigh CG, et al. Colonic transit in man is slowed by ondansetron (GR 38032F), a selective 5-hydroxytryptamine receptor (type 31 antagonist. Aliment Pharmacol Ther 1990; 4: 139-44
30. Talley NJ, Phillips SF, Haddad A, et al. GR 38032F (ondansetron). a selective 5-HT3 receptor antagonist, slows colonie transit in healthy man. Dig Dis Sci 1990; 35: 477-80
31. Allan SG. The 5HT3 antagonists: new generation antienieties. Curr Ther 1993:34: 15-8
32. Gyermek L. 5-HT3 receptors: pharmacologie and therapeutic aspects. J Clin Pharmacol 1995; 35: 845-55
33. Oxford AW, Bell JA, Kilpatrick GJ, et al. Ondansetron and related 5-HT3 antagonists: recent advances. Prog Med Chem 1992; 29: 239-70
34. Blier P, Bouchard C. Functional characterization of a 5-HT3 receptor which modulates the release of 5-HT in the guinea pig brain. Br J Pharmacol 1993, 108: 13-22
35. Nemeth PR, Gullikson GW. Gastrointestinal motility stimulating drugs and 5-HT receptors on myenteric neurons. Eur J Pharmacol 1989; 166: 387-91
36. Goyal RK, Hirano I. The enteric nervous system. N Engl J Med 1996; 334: 1106-15
37. Andrews PLR, Rapeport WG, Sanger GJ. Neuropharmacology of emesis induced by anti-cancer therapy. Trends Pharmacol Sci 1988; 9: 334-41
38. Maxton DG, Morris J, Whorwell PJ. Selective 5-hydroxytryptamine antagonism: a role in irritable bowel syndrome and functional dyspepsia? Aliment Pharmacol Ther 1996; 10: 595-9
39. Barr LC, Goodman WK, Price LH. Physical symptoms associated with paroxeline discontinuation [letter]. Am J Psychiatry 1994; 151: 289
40. Phillips SD. A possible paroxetine withdrawal syndrome. Am J Psychiatry 1995; 152: 645-6
41. Brown SGA, Prentice DA. Ondansetron in the treatment of theophylline overdose [letter]. Med J Aust 1992; 156: 512
42. Roberts JR, Carney S, Boyle SM, et al. Ondansetron quells drug-resistant emesis in theophylline poisoning. Am J Emerg Med 1993; 11:609-10
43. Dones I, Servello D, Ferrazza C, et al. Ondansetron as a treatment of intrathecal baclofen overdose: a case report [abstract]. J Neurology 1995; 242 Suppl. 2: 94
44. Bailey J, Potokar J, Nutt D. Can the GI disturbance produced by SSRIs be attenuated by a 5HT3 antagonist [abstract]? Neuropsychopharmacology 1994; 10 Suppl. Pt 2: 220
45. Wysowski DK, Bacsanyi J. Cisapride and fatal arrhythmia [letter]. N Engl J Med 1996; 335: 290-1